Coming back to post #6, because the follow-up matters more than the original answer.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
post #35 answers the question as asked. The question underneath it is different.
Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.
This follows post #40 rather than contradicting it.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.
post #57 is right about the mechanism and I think understates the practical bit.
Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.
This follows post #75 rather than contradicting it.
Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.
Read the full topic (140 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Prescription portability between countries — the long version
On the subject in the title: Prescription portability between countries — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
2 | 182 | 21h | |
|
Travelling with an injectable: documentation and practicalities
Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting an access outcome, dated, because everything…
|
+37 | 42 | 2.1k | 1d |
|
Personal import allowances, compared
On the subject in the title: Personal import allowances, compared Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of July 2026, in…
|
+5 | 9 | 3.2k | 7mo |
|
Prescription portability between countries
Prescription portability between countries — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
|
+104 | 114 | 6.1k | 3h |
|
Revisiting: Language barriers in accessing a prescription abroad
Posting this under the heading it deserves: Revisiting: Language barriers in accessing a prescription abroad Everything below is what sits behind that. Documenting an access outcome, dated, because everything…
|
+131 | 148 | 28k | 5mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
MHRA statements, read directly — the long version
On the subject in the title: MHRA statements, read directly — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 44k | 22mo | |
|
EU-wide position versus national implementation — what changed since
EU-wide position versus national implementation — what changed since Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included,…
|
+22 | 26 | 58k | 2mo |
|
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+7 | 11 | 39k | 3mo |
|
Travelling with an injectable: documentation and practicalities
Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting an access outcome, dated, because everything…
|
+37 | 42 | 2.1k | 1d |
|
Second pass at: Pharmacy supply in the UK and the questions you will be asked
Second pass at: Pharmacy supply in the UK and the questions you will be asked Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail…
|
+46 | 53 | 14k | 12mo |